- Home
- HIX vs VANI Comparison
HIX vs VANI Comparison
Compare HIX & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIX | VANI |
|---|---|---|
| Founded | 1998 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 376.5M | 91.9M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | HIX | VANI |
|---|---|---|
| Price | $4.25 | $1.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 449.5K | ★ 551.7K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | ★ 13.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.16 | $0.91 |
| 52 Week High | $5.08 | $1.92 |
Technical Indicators
Market Signals| Indicator | HIX | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 57.85 | 39.27 |
| Support Level | $4.22 | $1.16 |
| Resistance Level | $4.28 | $1.31 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 73.04 | 5.19 |
Price Performance
Historical ComparisonAbout HIX Western Asset High Income Fund II Inc.
Western Asset High Income Fund II Inc is a diversified closed-end management investment company. Its investment objective is to maximize current income by investing at least 80% of its net assets and borrowings for investment purposes in high-yield debt securities.
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.